RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Entrada Therapeutics Stock

Entrada Therapeutics Liabilities 2025

Entrada Therapeutics Liabilities

226.83 M USD

Ticker

TRDA

ISIN

US29384C1080

In 2025, Entrada Therapeutics's total liabilities amounted to 226.83 M USD, a 474.26% difference from the 39.5 M USD total liabilities in the previous year.

Entrada Therapeutics Aktienanalyse

What does Entrada Therapeutics do?

Entrada Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Entrada Therapeutics's Liabilities

Entrada Therapeutics's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Entrada Therapeutics's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Entrada Therapeutics's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Entrada Therapeutics's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Entrada Therapeutics’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Entrada Therapeutics stock

What is the level of liabilities of Entrada Therapeutics this year?

Entrada Therapeutics has a debt balance of 226.83 M USD this year.

What were the liabilities of Entrada Therapeutics compared to the previous year?

The liabilities of Entrada Therapeutics have increased by 474.26% increased compared to the previous year.

What are the consequences of high debt for investors of Entrada Therapeutics?

High liabilities can pose a risk for investors of Entrada Therapeutics, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Entrada Therapeutics?

Low liabilities mean that Entrada Therapeutics has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Entrada Therapeutics affect the company?

An increase in liabilities of Entrada Therapeutics can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Entrada Therapeutics affect the company?

A decrease in the liabilities of Entrada Therapeutics can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Entrada Therapeutics?

Some factors that can influence the liabilities of Entrada Therapeutics include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Entrada Therapeutics so important for investors?

The liabilities of Entrada Therapeutics are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Entrada Therapeutics take to modify the liabilities?

To change its liabilities, Entrada Therapeutics can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Entrada Therapeutics pay?

Over the past 12 months, Entrada Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Entrada Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Entrada Therapeutics?

The current dividend yield of Entrada Therapeutics is .

When does Entrada Therapeutics pay dividends?

Entrada Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Entrada Therapeutics?

Entrada Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Entrada Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Entrada Therapeutics located?

Entrada Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Entrada Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Entrada Therapeutics from 1/16/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 1/16/2025.

When did Entrada Therapeutics pay the last dividend?

The last dividend was paid out on 1/16/2025.

What was the dividend of Entrada Therapeutics in the year 2024?

In the year 2024, Entrada Therapeutics distributed 0 USD as dividends.

In which currency does Entrada Therapeutics pay out the dividend?

The dividends of Entrada Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Entrada Therapeutics

Our stock analysis for Entrada Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Entrada Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.